BioCryst prelim 2022 ORLADEYO rev $251.6M (+105% YoY); FY23 guide ≥$320M; BCX10013 data positive

BIOCRYST PHARMACEUTICALS INC

2022-FY EPS reported -$1.33 revenue$270,827,000

Prelim 2022 ORLADEYO net rev $251.6M (+105% YoY); Q4 rev $70.7M (+53% YoY).
FY2023 ORLADEYO net rev guidance no less than $320M; company expects peak sales of $1B.
Phase1 data for BCX10013 (oral Factor D inhibitor): >97% AP suppression at 110 mg single dose, safe/well-tolerated.
Advancing BCX10013 into patient studies mid-2023 for PNH and IgAN; expanding complement platform to C2 targets.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOCRYST PHARMACEUTICALS INC reported the fourth quarter and full year ended December 31, 2022 results: revenue $70.7 million. Guidance raised.

Period: the fourth quarter and full year ended December 31, 2022
Revenue: $70.7 million
Guidance: raised
Result: preliminary results

Exact text from the filing

for many years to come,” said Jon Stonehouse, president and chief executive officer of BioCryst. Preliminary, unaudited ORLADEYO net revenue in the fourth quarter of 2022 was $70.7 million (+53 percent y-o-y). Preliminary, unaudited ORLADEYO net revenue for full year 2022 was $251.6 million (+105 percent y-o-y). Fourth Quarter and Full Year 2022 ORLADEYO Revenue

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-23-000154

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.